A tale of two citizens: A state attorney general and a hematologist facilitate translation of research into us food and drug administration actions-a sonar report

Journal of Oncology Practice

Volumn 8, Issue 6, 2012, Pages

  Chen, Brian ^a,b,c,d,e   Restaino, John ^a,b,c,d,e   Norris, LeAnn ^a,b,c,d,e   Xirasagar, Sudha ^a,b,c,d,e   Qureshi, Zaina P ^a,b,c,d,e   McKoy, June M ^a,b,c,d,e   Lopez, Isaac S ^a,b,c,d,e   Trenery, Alyssa ^a,b,c,d,e   Murday, Alanna ^a,b,c,d,e   Kahn, Adam ^a,b,c,d,e   Mattison, Donald R ^a,b,c,d,e   Ray, Paul ^a,b,c,d,e   Sartor, Oliver ^a,b,c,d,e   Bennett, Charles L ^a,b,c,d,e,f  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Risk Sciences International   (Canada)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f University of South Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; THALIDOMIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CITIZENSHIP; DRUG APPROVAL; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG PACKAGING; DRUG SAFETY; ECHOLOCATION; ERYTHEMA NODOSUM LEPROSUM; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATION; LAWYER; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; OFF LABEL DRUG USE; PHASE 3 CLINICAL TRIAL (TOPIC); PROPHYLAXIS; RISK FACTOR; RISK MANAGEMENT; SKIN DISEASE; SOMNOLENCE; TRANSLATIONAL RESEARCH; UNITED STATES; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; CONNECTICUT; DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; HEMATOLOGY; HUMANS; LAWYERS; LOBBYING; OFF-LABEL USE; PUBLIC OPINION; THALIDOMIDE; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VENOUS THROMBOEMBOLISM;

EID: 84868577020     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000504     Document Type: Article

References (48)

1. US Food and Drug Administration: Warning letter to Celgene regarding off-label marketing. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/EnforcementActivitiesbyFDA/ WarningLettersandNoticeofViolationLetters toPharmaceuticalCompanies/UCM165843. pdf
2. State of Connecticut: Petition to require Celgene corporation to revise the labeling of Thalomid capsules to strengthen warnings of the potential for serious adverse events when prescribed in combination with other cancer treatment therapies. http://www.ct.gov/ag/lib/ag/press-releases/2005/health/ celgene-petition.pdf
3. Psaty BM, Burke SM: Protecting the health of the public-Institute of Medicine recommendations on drug safety. N Engl J Med 355:1753-1755, 2006
4. Carpenter DP: Reputation and the organizational politics of new drug review, in Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton, NJ, Princeton University Press, 2010
5. Hilts P: Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation. New York, NY, Alfred A. Knopf, 2003
6. McBride WG: Thalidomide and congenital abnormalities. Lancet 2:1358, 1961
7. Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6:303-306, 1965
8. Zeldis JB, Williams BA, Thomas SD, et al: S.T.E.P.S: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21:319-330, 1999
9. Uhl K, Cox E, Rogan R, et al: Thalidomide use in the US: Experience with pregnancy testing in the S.T.E.P.S. programme. Drug Saf 29:321-329, 2006
10. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
11. Evens A, Tallman MS, Singhal S, et al: FDA policies should be amended to allow pharmaceutical manufacturers to disseminate information regarding potentially fatal toxicities that occur with off-label use of oncology agents: A policy recommendation based on review of thalidomide-associated thromboembolism cases by the RADAR project. Blood 104, 2004 (abstr 265a)
12. US Food and Drug Administration, Center for Drug Evaluation and Research: Administrative and correspondence documents for Application 21-430 (thalidomide as a treatment for multiple myeloma). http://www.accessdata.fda.gov/drugsatfda- docs/nda/2006/021430s000-AdminCorres.pdf
13. US Food and Drug Administration: Regulatory review of lenalidomide as a treatment for 5q-myelodysplastic syndrome. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2005/021880s000-Revlimid-MedR.pdf
14. US Food and Drug Administration: Post-approval commitments. http://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm
15. US Food and Drug Administration: Revised FDA label for thalidomide, 2003. http://www.accessdata.fda.gov/drugsatfda-docs/label/2003/20785slr022,023,024- thalomid-lbl.pdf
16. US Food and Drug Administration: Revised FDA label for thalidomide, 2005. http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021430s000. 020785s031lbl.pdf
17. US Food and Drug Administration: Initial FDA label for lenalidomide, 2005. http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/021880lbl.pdf
18. US Food and Drug Administration: Revised FDA label for lenalidomide, 2006. http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021880s001.
19. Desai AA, Vogelzang NJ, Rini BI, et al: A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95:1629-1636, 2002
20. Zangari M, Anaissie E, Barlogie B, et al: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614-1615, 2001
21. Oncologic Drugs Advisory Committee: Meeting transcript: Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, 2003. http://www.accessdata.fda.gov/drugsatfda-docs/ nda/2006/021430s000-AdminCorres.pdf
22. US Food and Drug Administration: Citizen's petition to provide certification to Congress under Section 804 (l) of chapter VIII of the Federal Food, Drug, and Cosmetics Act and to authorize a pilot program for importation of prescription drugs in the state of Illinois. http://www.fda.gov/ohrms/ dockets/dailys/04/apr04/041404/04p-0177-cp00001-01-vol1.pdf
23. Harris G: Petition seeks warning on anticancer medications. http://www. nytimes.com/2005/05/04/health/04drug.html
24. Markey EJ: Conspiracy of silence: How the FDA allows drug companies to abuse the accelerated approval process. http://votesmart.org/public-statement/ 103059/conspiracy-of-silence-fda-allows-drug-companies-to-abuse-the- acceleratedapproval-process-companies-fail-to-conduct-follow-up-studies
25. Galson S: Letter to Richard Blumenthal, Connecticut Attorney General. http://www. ct.gov/ag/lib/ag/departments/thalomid-citizens-petition-response.pdf
26. Bennett CL, Angelotta C, Yarnold PR, et al: Thalidomide-and lenalidomideassociated thromboembolism among patients with cancer. JAMA 296:2558-2560, 2006
27. Rajkumar SV, Rosinol L, Hussein M, et al: Multicenter, randomized, double blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26:2171-2177, 2008
28. Palumbo A, Rajkumar SV, Dimopoulos MA, et al: Prevention of thalidomideand lenalidomide-associated thrombosis in myeloma. Leukemia 22:414-423, 2008
29. US Government Accountability Office: New drug approval: FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints. http://www.gao.gov/products/GAO-09-866
30. Johnson JR, Ning YM, Farrell A, et al: Accelerated approval of oncology products: The Food and Drug Administration experience. J Natl Cancer Inst 103:636-644, 2011
31. Oncologic Drugs Advisory Committee: Meeting transcript: Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/ Committees MeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM221998.pdf
32. Oncologic Drugs Advisory Committee: Meeting transcript: Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/ Committees MeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM245644.pdf
33. Osman K, Comenzo R, Rajkumar SV, et al: Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951-1952, 2001
34. Bennett CL, Schumock GT, Desai AA, et al: Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 113:603-606, 2002
35. US Food and Drug Administration: Thalidomide Pharmion information brochure. http://www.fda.gov/ohrms/dockets/05p-0167-cp00001-Tab-05-Thalidomide- Brochure-vol1.pdf
36. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
37. Clark TE, Edom N, Larson J, et al: Thalomid (thalidomide) capsules: A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 24:87-117, 2001
38. Center for Medicare & Medicaid Services: Demonstration projects and evaluation reports. http://www.cms.hhs.gov/researchers/demos/
39. Northwestern University: Toxicities and off-label drug use. http://www. northwestern.edu/newscenter/stories/2005/01/thalidomide.html
40. Lasser KE, Allen PD, Woolhandler SJ, et al: Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220, 2002
41. State of Connecticut: Petition to require Purdue Pharma LP to revise the labeling of OxyContin tablets to strengthen warnings of the greater potential for developing side effects and adverse drug reactions due to prescribing dosing frequencies in excess of the recommended guidelines. http://www.ct.gov/ag/lib/ ag/health/citizenspetitionunredacted.pdf
42. Knight R, DeLap RJ, Zeldis JB: Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079-2080, 2006
43. Rizzo J, Brouwers M, Hurley P, et al: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28:4996-5010, 2010
44. Evens AE, Tallman MS, Singhal S, et al: Thalidomide-associated thromboembolism in the off-label clinical settings: An analysis of pharmacovigilance activities of the manufacturer and the Food and Drug Administration. http://www.fda.gov/ohrms/dockets/dockets/05p0167/05p-0167- cp00001-Tab-03-RADAR-DRAFT-vol1.pdf
45. Lyman G, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505, 2007
46. US Food and Drug Administration: Making your voice heard at FDA: How to comment on proposed regulations and submit petitions. http://www.fda.gov/ AboutFDA/ContactFDA/CommentonRegulations/default.htm
47. Carpenter D, Zucker EJ, Avorn J: Drug-review deadlines and safety problems. N Engl J Med 358:1354-1361, 2008
48. Food and Drug Administration Amendments Act of 2007. http://www. fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmetic ActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministration AmendmentsActof2007/FullTextofFDAAALaw/default.htm